Welcome to Trends-in-Medicine, offering independent, cutting-edge articles and information on drugs and devices in development. Our subscribers have access to news and analysis on the latest data, regulatory issues, and trends of interest to the healthcare community.

Quick Takes for May 4, 2025

AACR Oncology Industry Partnering Event

In a special pre-AACR event, 17 pharmas and biotechs talked about their focus in oncology, their pipeline, and answered questions. Key takeaways included: More attention needs to be paid to what China is doing and to the role of artificial intelligence., Most big companies are open to collaborations with smaller companies with good science, and the key drug classes highlighted included, ADCs, bispecifics, CAR Ts, immunotherapies, menin inhibitors, protein degraders, radiopharmaceuticals, and T-cell engagers

PainConnect

The PainConnect meeting, sponsored by the American Academy of Pain Medicine (AAPM), offered an opportunity to learn more about the outlook for a newly approved non-opioid (Vertex's Journavx) and two new pain medications in development -- Tris Pharma's cebranopadol and Tonix Pharmaceuticals' TNX-102 SL.

BULLETIN: ESMO TAT and ELCC

March was a busy month for the European Society for Medical Oncology (ESMO), with two major conferences in Paris: the ESMO Targeted Anticancer Therapies (TAT) Congress and the European Lung Cancer Congress (ELCC). Neither meeting was virtual, but ESMO arranged two zoom sessions with reporters. Here are some highlights from those sessions.

Dermatology-Part 1

Drug development is alive and well in dermatology, and among the interesting data on new drugs/new uses for existing drugs presented in a latebreaker session at AAD this year were:
• Alumis’ ESK-001, a TYK2 inhibitor for psoriasis.
• Johnson & Johnson/Janssen Biotech and Protagonist Therapeutics’ icotrokinra, an oral IL-23R inhibitor for psoriasis.
• Jasper Therapeutics’ briquilimab, an anti-CD117 for chronic spontaneous urticaria.

Dermatology-Part 2

Dermatology continues to be a hot area for drug development – both new drugs and new uses for existing drugs. Among the studies that stood out this year at AAD were:
• Leo Pharma’s Anzupgo (delgocitinib), a JAK inhibitor in hand eczema
• Regeneron Pharmaceuticals and Sanofi’s Dupixent (dupilumab), an anti-IL-4R in bullous pemphigoid
• Bristol Myers Squibb’s Sotyktu (deucravacitinib), a TYK2 inhibitor for lichen planopilaris
• Lilly’s Olumiant (baricitinib), a JAK inhibitor for adolescent alopecia areata

Angiogenesis

This conference offered a great update on 13 different drugs, both approved and in development, to treat dry AMD, geography atrophy, wet AMD, and DME.